New dual-action insulin to help people who can't feel low blood sugar
Official title: Dual Agonist Insulins for Treating Diabetics with Impaired Awareness ofHypoglycemia (IAH)
Funded at Amidebio, LLC · NIH-11176960 · Data updated 2026-11-12
Testing a dual-action insulin designed to prevent dangerous low blood sugars in adults with diabetes who have impaired awareness of hypoglycemia.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Amidebio, LLC NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $999,468 |
| NIH project number | 5R44DK141357-02 |
| Project ID | NIH-11176960 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults (age 21 and older) with diabetes who have impaired awareness of hypoglycemia or frequent insulin-related low blood sugars would be the intended participants.
✕Less likely to help
People who do not have impaired hypoglycemia awareness, those not treated with insulin, pregnant individuals, or people with specific medical exclusions may not benefit or be eligible.
What this research studies
You would be hearing about a new drug called a molecular artificial pancreas, a dual-acting insulin designed to stop low blood sugar before it becomes dangerous. The company will make and formulate these drug candidates and move directly into Phase II testing to see how they work in people. Early lab and preclinical work showed the approach can prevent hypoglycemia at high doses, and this project aims to test safety and benefit under clinical supervision. Participants would have blood sugar and symptoms closely monitored while receiving the study medication.
Why it matters
Potential benefit: If successful, this approach could reduce severe low-blood-sugar episodes and lower emergency visits for people with impaired hypoglycemia awareness.
How similar studies have gone: Preclinical and early laboratory studies have shown promising prevention of hypoglycemia, but human effectiveness is still largely unproven and the approach is relatively novel.
Where this research is happening
-
Amidebio, LLC
Louisville, United States Active
Researchers
- Principal investigator: Fludzinski, Pawel — Amidebio, LLC
- Study coordinator: Fludzinski, Pawel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.